Dong‐Seok Yim - Concepedia

Author

Dong‐Seok Yim

Catholic University of Korea ORCID

Also Known As

D YIM, D Yim, D. S. YIM, D. Yim, D.-S. Yim, D.S. Yim, Dong S. Yim, Dong Seok Yim, Dong-Seok Yim, Dong-Suk Yim

163

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Catholic University of Korea The Catholic University of Korea Seoul St. Mary's Hospital Seoul National University Samsung Medical Center Sungkyunkwan University

About

Dong‐Seok Yim is an author at Catholic University of Korea specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	22	586
2	Health Sciences	5	5	113
3	Public Health	4	4	142
4	Biochemistry	2	2	35
5	Education	1	1	16

Dong‐Seok Yim

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Relationship between the Val158Met polymorphism of catechol O-methyl transferase and breast cancer Dong‐Seok Yim, Sue K. Park, Keun-Young Yoo, Pharmacogenetics	2001	100
Population Pharmacokinetic Analysis and Simulation of the Time‐Concentration Profile of Etanercept in Pediatric Patients With Juvenile Rheumatoid Arthritis Dong‐Seok Yim, Honghui Zhou, Mary Buckwalter, The Journal of Clinical Pharmacology	2005	79
Leveraging Prior Quantitative Knowledge to Guide Drug Development Decisions and Regulatory Science Recommendations: Impact of FDA Pharmacometrics During 2004–2006 Yaning Wang, Atul Bhattaram, Pravin Jadhav, The Journal of Clinical Pharmacology Prior Quantitative KnowledgeQuantitative PharmacologyPharmacotherapyRegulatory Science RecommendationsTranslational Medicine	2008	72
Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients Si‐Hyun Kim, Dong‐Seok Yim, Su‐Mi Choi, International Journal of Infectious Diseases	2011	64
Population pharmacokinetics of meropenem in burn patients K. Doh, Henry H. Woo, Jun Hur, Journal of Antimicrobial Chemotherapy	2010	55
First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors Filip Jankú, Seung‐Hoon Beom, Yong Wha Moon, Investigational New Drugs	2022	54
Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19 Joo‐Youn Cho, Kyung‐Sang Yu, In‐Jin Jang, British Journal of Clinical Pharmacology	2002	50
A Population Pharmacokinetic–Pharmacodynamic Model for Simvastatin that Predicts Low‐Density Lipoprotein‐Cholesterol Reduction in Patients with Primary Hyperlipidaemia Jimyon Kim, Byung‐Jin Ahn, Hong‐Seok Chae, Basic & Clinical Pharmacology & Toxicology Simvastatin 40HyperlipidemiaPharmacotherapyTurnover ModelLow‐density Lipoprotein‐cholesterol Reduction	2011	41
Combined effect of GSTM1, GSTT1, and COMT genotypes in individual Sue K. Park, Dong‐Seok Yim, Kyung‐Sik Yoon, Breast Cancer Research and Treatment Allelic VariantGenetic DeterminantGenotype-phenotype AssociationMedicineGenetics	2004	41
Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β‐cyclodextrin in haematological patients with renal impairment Si‐Hyun Kim, Jae‐Cheol Kwon, Chulmin Park, Mycoses	2016	37

Page 1